2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Checkpoint Inhibitor, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Diseases, Lymphoid Malignancies, Lymphomas, Measurable Residual Disease, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly, Pediatric
PAPER

1942 IPH6501, a tetraspecific CD20-targeted NK cell engager, for relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL): Results from a phase 1/2 study

Lorenzo Falchi, MD, Fontanet Bijou2, Akil Merchant I, MD3, Jake Shortt, MBBS, FRACP, FRCPA, PhD4, Régis Costello, MD, PhD5, Geoff Chong, MD, PhD6, Benoit Tessoulin, MD, PhD7, Franck Morschhauser8, Swetha Thiruvengadam, MD9, Dilan Anil Patel, MD10, Joshua D. Brody, MD11, Ariane Lafabrie12, Carine Paturel13, Constance Vagne14, Markus Jensen, MD15, Julien Viotti16, Jan Pintoffl, MD17, Emmanuel Bachy I, MD, PhD18
1 Memorial Sloan Kettering Cancer Center, New York, United States
2 Institut Bergonie, Bordeaux, France
3 Cedars Sinai Medical Center, Los Angeles, California, United States
4 Monash Health and Monash University, City of Monash, Victoria, Australia
5 Hopital De La Timone, Marseille, France
6 Austin Health, Heidelberg, Victoria, Australia
7 Centre Hospitalier Universitaire De Nantes, Nantes, France
8 Centre Hospitalier Universitaire Lille, Lille, France
9 City of Hope National Medical Center, Duarte, California, United States
10 Siteman Cancer Center - Washington University Medical Campus Location, St. Louis, Missouri, United States
11 Icahn School Of Medicine At Mount Sinai, New York, United States
12 Innate Pharma SA, Marseille, France
13 Innate Pharma SA, Marseille, France
14 Innate Pharma SA, Marseille, France
15 Innate Pharma SA, Marseille, France
16 Innate Pharma SA, Marseille, France
17 Innate Pharma SA, Marseille, France
18 Hospices Civils De Lyon - Hopital Lyon Sud, Lyon, France

Background: Targeted T-cell therapies have transformed the care of relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL), but treatment options remain limited for patients who are ineligible for, non-responsive to, or relapsed after therapy. To address this unmet need, leveraging natural killer (NK) cells represents a potential novel treatment strategy. IPH6501 is a first-in-class tetraspecific antibody-based NK cell engager targeting both CD16a and NKp46 receptors on NK cells, CD20 on B-NHL cells. It includes an engineered IL-2 variant to limit Treg activation and IL-2-related side effects and induce NK cell proliferation.

Methods: IPH6501-101 is a first-in-human, multicenter, Phase 1/2 study of IPH6501 in patients with R/R B-NHL. Eligible participants included adults with advanced, histologically confirmed CD20+ B-NHL with an Eastern Cooperative Oncology Group (ECOG) Performance Status ≤2, and they were required to have received ≥2 prior systemic therapies, including at least an anti-CD20 antibody.

The study had a dose-escalation with backfilling and a 3+3 design to determine the maximum tolerated dose (MTD) or the highest dose, starting at 15 µg/kg every 3 weeks (Q3W) up to planned 400 µg/kg. Dose escalation occurred in the absence of dose-limiting toxicities (DLTs), grade ≥2 cytokine release syndrome (CRS) and grade ≥2 neurotoxicity. Dose increments were based on the occurrence of DLTs and Grade ≥2 adverse events. Primary endpoints were incidence of DLTs, safety and tolerability; key secondary endpoints were preliminary efficacy and pharmacokinetics (PK). The study was conducted in the United States, Australia, and France.

Results: Overall, 23 patients were treated in the dose escalation, from 15 µg/kg up to 225 µg/kg Q3W. Median age was 70 years (range, 32–89) and 69.6% were male. The most common histologies were diffuse large B-cell lymphoma, not otherwise specified (56.5%) and follicular lymphoma (21.7%). Patients had received a median of 9 (range, 2–18) prior therapies, including CD20-directed therapies, alkylating agents, anthracyclines, monoclonal antibodies (mAbs), antibody-drug conjugates and CAR-T therapy. All patients received prior treatment with CD20-directed mAbs, and 48% and 43% received prior treatment with T-cell engagers and CAR-T cells, respectively.

In the safety-evaluable population (N=23), 22 patients (95.7%) experienced ≥1 treatment-emergent adverse event (TEAE), in 17 patients TEAEs were considered at least possibly related to IPH6501. The most common TEAEs were CRS (65.2%) and laboratory abnormalities/investigations (47.8%). Capillary leak syndrome was not observed. Grade ≥3 TEAEs occurred in 17 patients (73.9%), 8 cases (34.8%) were considered related, with neutropenia/decreased neutrophil count being the most common event occurring in 3 patients (13%) each. Serious adverse events (SAEs) were reported in 15 patients (65.2%). No TEAEs led to dose interruption or dose reduction.

At 225 µg/kg, one patient developed a DLT (Grade ≥3 non-hematological toxicity), 2 patients developed Grade 2 CRS, and 1 patient developed a Grade 2 neurotoxicity. Thus, MTD was determined at 150 µg/kg.

Among the 23 treated patients, the best overall response was complete response (CR) in 1 patient (4.3%), partial response (PR) in 2 (8.7%), and stable disease (SD) in 5 (21.7%) for a disease control rate (CR+PR+SD) of 34.8%. Median follow-up was 15.29 weeks (minimum 1.7, maximum 89.0). Fourteen patients (61%) were alive at last follow-up.

IPH6501 PK was linear up to the highest dose tested. Despite a short half-life of <48 hours, the IPH6501-induced pharmacodynamic activity was long-lasting, supporting Q3W dosing. Pharmacodynamic signals included circulating B-cell depletion (when B-cells detected at baseline), NK-cell proliferation up to 3 weeks post administration, low T-cell and Treg proliferation, low IL-6 and TNF-a release and in few patients high IFN-g  at 2 and 4 hours post administration.

Conclusion: IPH6501 demonstrated a manageable safety profile, with an MTD of 150 µg/kg Q3W. Pharmacodynamics were consistent with the proposed mechanism of action for IPH6501, including sustained NK-cell proliferation and B-cell depletion. Objective responses, including one CR, were observed in this heavily pretreated population. The findings provide clinical evidence for the feasibility of engaging NK cells with a tetraspecific antibody and contribute to the understanding of NK cell-based immunotherapies in B-cell NHL.

Lorenzo Falchi, MD: Genmab - Honoraria; Kite - Honoraria; AbbVie - Honoraria; Roche - Honoraria; AbbVie - Research Funding; Roche - Research Funding; Innate Pharma - Research Funding; Genentech - Research Funding; AstraZeneca - Research Funding; BeOne Medicines - Research Funding; Genmab - Research Funding; Genmab - Consultancy (Includes expert testimony); Seagen - Consultancy (Includes expert testimony); Merck - Consultancy (Includes expert testimony); Ipsen - Consultancy (Includes expert testimony); Johnson & Johnson - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); ADC Therapeutics - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); Evolveimmune - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); Chugai - Consultancy (Includes expert testimony); Roche - Consultancy (Includes expert testimony); Regeneron - Consultancy (Includes expert testimony); Genentech - Consultancy (Includes expert testimony)